Press Releases Idorsia Ltd

Equities

IDIA

CH0363463438

Market Closed - Swiss Exchange Other stock markets 11:30:44 2024-05-03 am EDT			5-day change	1st Jan Change
2.012 ^CHF	-0.98%		+5.89%	-4.82%

May. 02	Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond	MT
Apr. 26	Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond	May. 01	GL
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension	Apr. 26	GL
Idorsia publishes an invitation to a bondholder meeting	Apr. 23	GL
Idorsia : On April 17, 2024, Idorsia published an Unaudited Financial Status as of March 31, 2024, in connection with an upcoming bondholder meeting. Unaudited Financial Status	Apr. 17	PU
Idorsia publishes a Financial Status required for an upcoming bondholder meeting	Apr. 17	GL
Idorsia takes steps to address short-term liquidity needs	Apr. 11	GL
Idorsia thanks Guy Braunstein for his years of service as he retires	Mar. 22	GL
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives	Mar. 20	GL
Idorsia and Viatris successfully close the transaction for the global research and development collaboration	Mar. 18	GL
Idorsia and Viatris enter into a significant global research and development collaboration	Feb. 28	GL
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration	Feb. 28	PR
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation	Jan. 10	GL
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023	Nov. 03	GL
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value	23-10-24	GL
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023	23-10-23	GL
Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call	23-10-17	GL
Idorsia reacquires the world-wide rights to aprocitentan	23-09-06	GL
Tausif Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager	23-09-01	AQ
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value	23-07-25	GL
Idorsia announces a cost reduction initiative to be implemented by the end of 2023	23-07-21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Idorsia Ltd

Equities

IDIA

CH0363463438

Press Releases

Filters